B Charpentier
Overview
Explore the profile of B Charpentier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
319
Citations
1994
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Migus A, Netter P, Boitard C, Clement B, Allilaire J, Ardaillou R, et al.
Bull Acad Natl Med
. 2020 Aug;
204(8):748-760.
PMID: 32836262
No abstract available.
2.
Migus A, Netter P, Boitard C, Clement B, Allilaire J, Ardaillou R, et al.
Bull Acad Natl Med
. 2020 Aug;
204(9):e145-e156.
PMID: 32836261
No abstract available.
3.
Kramer B, Albano L, Banas B, Charpentier B, Backman L, Tedesco-Silva Jr H, et al.
Transplant Proc
. 2017 Nov;
49(9):2040-2049.
PMID: 29149958
Background: Two large, prospective studies (12-03; OSAKA) compared the efficacy and tolerability of prolonged-release versus immediate-release tacrolimus in kidney transplant patients also receiving mycophenolate mofetil and low-dose corticosteroids (without induction...
4.
Gatault P, Kamar N, Buchler M, Colosio C, Bertrand D, Durrbach A, et al.
Am J Transplant
. 2016 Nov;
17(5):1370-1379.
PMID: 27862923
The aim of this study (ClinicalTrials.gov, NCT01744470) was to determine the efficacy and safety of two different doses of extended-release tacrolimus (TacER) in kidney transplant recipients (KTRs) between 4 and...
5.
Hellemans R, Hazzan M, Durand D, Mourad G, Lang P, Kessler M, et al.
Am J Transplant
. 2015 Feb;
15(7):1923-32.
PMID: 25707875
We previously reported a randomized controlled trial in which 227 de novo deceased-donor kidney transplant recipients were randomized to rabbit antithymocyte (rATG, Thymoglobulin) or daclizumab if they were considered to...
6.
Fears R, Kelleher D, Tresguerres J, Charpentier B, Popescu I, Souhami R
QJM
. 2014 Jun;
107(8):603-5.
PMID: 24970762
Previous contributions to Quarterly Journal of Medicine have drawn attention to the work of FEAM, the Federation of European Academies of Medicine, in collaboration with others, in exploring and explaining...
7.
Clement T, Salone V, Charpentier B, Jouzeau J, Bianchi A
Biomed Mater Eng
. 2014 Jun;
24(1 Suppl):3-16.
PMID: 24928913
Osteoarthritis (OA) is a whole-joint disease characterized by cartilage degradation and mineralization associated with chondrocyte phenotype changes, subchondral bone sclerosis and mild synovial inflammation. The extracellular levels of inorganic phosphate...
8.
Charpentier B, Medina Pestana J, Del C Rial M, Rostaing L, Grinyo J, Vanrenterghem Y, et al.
Am J Transplant
. 2013 Oct;
13(11):2884-91.
PMID: 24103072
Patients in the BENEFIT-EXT study received extended criteria donor kidneys and a more intensive (MI) or less intensive (LI) belatacept immunosuppression regimen, or cyclosporine A (CsA). Patients who remained on...
9.
Rostaing L, Charpentier B, Glyda M, Rigotti P, Hettich F, Franks B, et al.
Am J Transplant
. 2013 Jun;
13(7):1724-33.
PMID: 23730730
Memory T cells play a central role in mediating allograft rejection and are a rational target for immunosuppressive therapy. Alefacept is a recombinant LFA3/IgG1 fusion protein that reduces the number...
10.
Vincenti F, Larsen C, Alberu J, Bresnahan B, Garcia V, Kothari J, et al.
Am J Transplant
. 2011 Oct;
12(1):210-7.
PMID: 21992533
The clinical profile of belatacept in kidney transplant recipients was evaluated to determine if earlier results in the BENEFIT study were sustained at 3 years. BENEFIT is a randomized 3...